EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Nakasa Fek
Country: Indonesia
Language: English (Spanish)
Genre: Photos
Published (Last): 9 December 2015
Pages: 138
PDF File Size: 16.57 Mb
ePub File Size: 13.26 Mb
ISBN: 539-2-57445-926-1
Downloads: 3836
Price: Free* [*Free Regsitration Required]
Uploader: Zolosida

The presence of one or more of the contraindications against any of the study drugs. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

SchizophreniaSchizophreniform disorderSchizoaffective disorder. Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. The principal investigators are Prof.

The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug.

EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Quality of life 6.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Multicentre, randomised active controlled, parallel group trial. Analysis was by intention to treat. Rationale and design of the trial. This effort represents the first independently designed trans-European schizophrenia treatment trial. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

  DS18S20 DATASHEET PDF

PfizerAstraZenecaSanofi-Aventis. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study eufst range. Natural history of schizophrenia. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

This outcome is assessed at regular time intervals until 12 months after recruitment. The presence of one or more of the contra-indications against any of the study drugs. Genetic determinants of response to antipsychotic drugs 9.

The primary outcome measure was all-cause treatment discontinuation. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.

Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Result of results found for within.

  ALEXANDRE DUMAS IL VISCONTE DI BRAGELONNE PDF

At regular time intervals patients are followed-up until 12 months after recruitment: Most studies comparing second generation antipsychotics with classical stdy have been conducted in more or less chronic schizophrenia patients. At present, more than patients have been recruited and randomized in the following countries: Previous Trial Back to results Next Trial.

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: We did an open randomised controlled trial of haloperidol versus second-generation eifest drugs in 50 sites, in 14 countries.

We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Eligibility Participant inclusion criteria 1.

Ethics approval received from the local medical ethics committee. Home Who are we? Second-generation antipsychotic drugs were introduced over a decade ago studu the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. Intolerance to one of the drugs in this study; 4.

The study should eufesf finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics.

Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range.

VPN